Loading…
Chinese premium cosmetics and skincare brand founded by celebrity makeup artist Mao Geping.
Chinese premium cosmetics and skincare brand founded by celebrity makeup artist Mao Geping.
Sells through its own counters and stores, online channels such as Tmall and Douyin, and department stores, relying on its founder's name and artist-led product design to hold premium prices rather than on mass-market volume.
In one line: A Chinese prestige-beauty brand, like a domestic Estée Lauder line.
Moat: narrow (brand). Founder's celebrity status and reputation as a premium domestic beauty brand differentiate it from mass-market peers.
Headquarters: Beijing, China · Founded: 2000 · Employees: 4,488
Size Mao Geping Cosmetics (1318.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $4.92B, the 255th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$53.65 on 6 Nov 2026.
Performance Over six months the shares fell 28.5%, against -1.7% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 32.2% over the last twelve months (peer median +5.6%); the operating margin is 30.6% (peer median 12.4%).
Valuation It trades at 15.0× forward earnings against a peer median of 20.9× (6th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is -36 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 93.1 points above its cost of capital (8.1% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$6.42B | HK$5.48B | HK$4.21B | HK$3.19B | HK$1.94B |
| Revenue growth | — | +30% | +32% | +65% | — |
| Gross profit | HK$5.32B | HK$4.52B | HK$3.52B | HK$2.64B | HK$1.50B |
| EBITDA | HK$2.08B | HK$1.78B | HK$1.29B | HK$1.01B | HK$591M |
| Net income | HK$1.50B | HK$1.31B | HK$955M | HK$731M | HK$405M |
| Free cash flow | HK$1.30B | HK$1.12B | HK$442M | HK$715M | HK$427M |
| Capital expenditure | HK$250M | HK$203M | HK$668M | HK$81.2M | HK$40.1M |
| Total debt | n/a | HK$85.1M | HK$387M | HK$42.9M | HK$61.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Mao Geping Cosmetics 1318.HK | $4.92B | -28% | +32% | 31% | 15.0× | 4.7% |
| Giant Biogene 2367.HK | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% |
| Proya Cosmetics 603605.SS | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% |
| Estée Lauder Companies (The) EL | $39.9B | +28% | +6% | 13% | 31.1× | 16.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1318.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.0% | -0.7% | 3rd highest of 21 |
| 6-month return | -28.5% | -1.7% | 3rd lowest of 21 |
| Distance from 52-week high | -44.4% | -21.9% | 3rd lowest of 21 |
| Revenue growth (TTM) | +32.2% | +5.6% | 3rd highest of 21 |
| Operating margin | 30.6% | 12.4% | 3rd highest of 21 |
| Forward P/E | 15.0× | 20.9× | 6th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 4.7% | 4.0% | 10th most demanding of 20 |
| Growth delivered (Del g) | +41.1% | +4.6% | 2nd highest of 20 |
| Hurdle (Req g minus delivered) | -36.4 pp | -1.7 pp | 3rd least demanding of 20 |
| ROIC minus cost of capital | +93.1 pp | +3.4 pp | 2nd highest of 20 |
| EV / EBITDA | 16.5× | 15.9× | 7th most expensive of 15 |
| Net debt / EBITDA | -2.0× | -0.3× | 3rd least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.92B | -28% | +32% | 31% | 15.0× | 4.7% | +41.1% |
| Cupid CUPID.NS | India | $4.83B | +158% | +122% | 34% | n/a | n/a | n/a |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.83B | -23% | +9% | 28% | 32.2× | 30.8% | +4.5% |
| Reynolds Consumer Products REYN | United States | $5.08B | +10% | +2% | 14% | 14.6× | -0.2% | +2.7% |
| Interparfums IPAR | United States | $4.34B | +43% | +3% | 17% | 29.0× | 10.9% | +22.5% |
| Amorepacific 090430.KS | South Korea | $6.03B | -1% | +10% | 9% | 23.8× | 4.0% | -0.8% |
| Rohto Pharmaceutical 4527.T | Japan | $3.97B | +17% | +10% | 12% | 16.7× | -2.1% | +13.7% |
| Coty COTY | United States | $3.57B | +64% | -1% | 5% | 13.3× | 11.3% | +4.6% |
| e.l.f. Beauty ELF | United States | $6.85B | +91% | +31% | 12% | 35.4× | 27.9% | +38.8% |
| APR 278470.KS | South Korea | $7.04B | -40% | +119% | 23% | 17.4× | -1.4% | +47.3% |
| Dabur India DABUR.NS | India | $7.13B | -19% | +9% | 15% | 32.1× | 27.3% | +6.6% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.28B | -16% | +2% | 11% | 9.1× | -8.8% | -0.1% |
| Lion 4912.T | Japan | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% | +3.5% |
| Proya Cosmetics 603605.SS | China | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% | +23.1% |
| Giant Biogene 2367.HK | Hong Kong | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% | +34.9% |
| Winner Medical 300888.SZ | China | $2.69B | -2% | +4% | 11% | 20.9× | -4.3% | -2.6% |
| Godrej Consumer Products GODREJCP.NS | India | $9.19B | -18% | +12% | 18% | 37.0× | 31.7% | +6.6% |
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Shiseido 4911.T | Japan | $9.52B | +20% | +5% | 4% | 32.8× | 17.5% | +1.0% |